Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Cristal Delivery announces successful seed financing round


Dutch nanomedicine company Cristal Delivery B.V. announces the successful completion of a seed round to move its first product, CriPec® docetaxel, into clinical development, and to expand the company’s technology platform. The financing round was led by BioGeneration Ventures and Thuja Capital. The founding investors, including Utrecht University Holding, also participated in this round.


Cristal Delivery develops a proprietary polymeric platform, registered as CriPec®, that allows for the transiently stable entrapment of active compounds in nanoparticles. Numerous in vivo validation studies confirm that CriPec®nanoparticles significantly improve the efficacy and safety of various entrapped compounds when compared to conventional drugs used in several therapeutic areas. The clinical development of CriPec® docetaxel is part of company’s strategy to leverage CriPec® into a portfolio of best-in-class products using small molecules, peptides, and actively targeted nanoparticles.

Cristal Delivery B.V. was founded in April 2011, as a spin-off of the Department of Pharmaceutics of Utrecht University by Cristianne Rijcken, PharmD PhD, and Joost Holthuis, PhD.

“In these challenging times, it is a major step to have these two new investors (BioGeneration Ventures and Thuja Capital) on board,” said Rijcken. “I consider it as a real validation of the potential of Cristal Delivery and its CriPec® products.”

“Cristal Delivery is developing exciting new nanomedicines that we think have a very significant potential in the market,’ said BioGeneration’s Edward van Wezel. “We have followed the founding team from a very early stage onwards and we believe they have what it takes to grow Cristal Delivery into a successful enterprise.”

Thuja’s Michel Briejer, PhD, characterised Cristal Delivery as “one of those rare start-up companies that have succeeded to build a convincing preclinical data package to demonstrate the potential of their product-enabling technology platform, combined with a good mix of entrepreneurship and experience at the management level,” he said. “We are therefore glad to come on board and help to build success.”

Edward van Wezel, of BioGeneration Ventures, and Michel Briejer, of Thuja Capital, will both join Cristal Delivery’s Supervisory Board.

Find out more
For more information about Cristal Delivery and its CriPec® nanomedicine platform technology, please visit the website or contact:

Cristianne Rijcken, PharmD PhD
Chief Executive Officer, Cristal Delivery B.V.
+31 30 430 0222
Cristianne.Rijcken@cristaldelivery.com
www.cristaldelivery.com


About BioGeneration Ventures
BioGeneration Ventures invests in seed and early stage Dutch Life Sciences companies. BioGeneration’s team specialises in developing the value of novel and innovative technologies, and in the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), Netherlands Organisation for Scientific Research (NWO), the Holding of the University of Leiden, and ABN-AMRO. BioGeneration Ventures cooperates closely with Forbion Capital Partners.

About Thuja Capital
Thuja Capital Healthcare Seed Fund B.V. (TCHSF) is a venture capital fund structured to invest in early-stage life sciences companies based in The Netherlands, with a focus on therapeutics, diagnostics, and medical devices. TCHSF, managed by Thuja Capital Management B.V. (Thuja Capital), has a long-standing and successful track record in life sciences investments. Thuja Capital actively supports and helps portfolio companies to strengthen and grow their business. Apart from managing the TCHSF, Thuja Capital is also the exclusive manager of the Thuja Capital Healthcare Fund, and of AlpInvest Partners' portfolio of early stage life sciences companies.


Publisher Contact Information:

Cristal Delivery
+31 30 430 0222
Cristianne.Rijcken@cristaldelivery.com

Company profile of Cristal Therapeutics (formerly Cristal Delivery)
Past press releases of Cristal Therapeutics (formerly Cristal Delivery).

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.